Health Prob Civil.
1. International Agency for Research on Cancer. Global cancer burden growing, amidst mounting need for services. Press Release No. 345 [Internet]. Geneva: World Health Organization; 2024 [access 2025 Jun 17]. Available from: https://www.iarc.who.int/wp-content/uploads/2024/02/pr345_E.pdf
2.
Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019; 16(2): 93-103. https://doi.org/10.1080/14789450.2019.1559062
3.
Zou J, Wang E. Cancer biomarker discovery for precision medicine: new progress. Curr Med Chem. 2019; 26(42): 7655-7671. https://doi.org/10.2174/0929867325666180718164712
4.
Srivastava A, Creek DJ. Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics. Proteomics. 2019; 19(10): e1700448. https://doi.org/10.1002/pmic.201700448
5.
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024; 9(1): 132. https://doi.org/10.1038/s41392-024-01823-2
6.
Ren AH, Fiala CA, Diamandis EP, Kulasingam V. Pitfalls in cancer biomarker discovery and validation with emphasis on circulating tumor DNA. Cancer Epidemiol Biomarkers Prev. 2020; 29(12): 2568-2574. https://doi.org/10.1158/1055-9965.EPI-20-0074
7.
Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015; 7(6): 1003-1015. https://doi.org/10.2217/epi.15.56
8.
Henry NL, Hayes DF. Cancer biomarkers. Molecular Oncology. 2012; 6(2): 140-146. https://doi.org/10.1016/j.molonc.2012.01.010
9.
DeLouize AM, Eick G, Karam SD, Snodgrass JJ. Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research. American Journal of Human Biology. 2022; 34(11): e23665. https://doi.org/10.1002/ajhb.23665
10.
Pal M, Muinao T, Boruah HPD, Mahindroo N. Current advances in prognostic and diagnostic biomarkers for solid cancers: detection techniques and future challenges. Biomedicine & Pharmacotherapy. 2022; 146: 112488. https://doi.org/10.1016/j.biopha.2021.112488
11.
Sarhadi VK, Armengol G. Molecular biomarkers in cancer. Biomolecules. 2022; 12(8): 1021. https://doi.org/10.3390/biom12081021
12.
Kerr DJ, Yang L. Personalising cancer medicine with prognostic markers. eBioMedicine. 2021; 72. https://doi.org/10.1016/j.ebiom.2021.103577
13.
Louie AD, Huntington K, Carlsen L, Zhou L, El-Deiry WS. Integrating molecular biomarker inputs into development and use of clinical cancer therapeutics. Frontiers in Pharmacology. 2021; 12. https://doi.org/10.3389/fphar.2021.747194
14.
Karadag A. [Personalized medicine, integrated multi-omics artificial intelligence-based smart health system]. Turkish Association for Cancer Research and Control; 2022 (in Turkish).
15.
Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, Eeles RA, et al. BRCA1, BRCA2, and associated cancer risks and management for male patients: a review. JAMA Oncol. 2024; 10(9): 1272-1281. https://doi.org/10.1001/jamaoncol.2024.2185 Erratum in: JAMA Oncol. 2025; 11(2): 189. https://doi.org/10.1001/jamaoncol.2024.6584
16.
Chen J, Wu X, Han G, Xu C. Single-cell transcriptomic insights into ccRCC: a stemness gene signature for prognosis and treatment response prediction. Discov Onc. 2025; 16: 1862. https://doi.org/10.1007/s12672-025-03664-z
17.
Simão TA, Gomes JV, de Paula JG, de Oliveira Ribeiro SC. Perspective chapter: advancements in cancer biomarkers – transforming diagnostics and therapeutic strategies in precision oncology. In: Gaina G, editor. Molecular diagnostics – current approaches and their clinical applications. London: IntechOpen; 2025. https://doi.org/10.5772/intechopen.1009980
18.
Abbasi AF, Naveed S, Asim MN, Sajjad M, Vollmer S, Dengel A. Artificial intelligence powered biomarker discovery: a large-scale analysis of 236 studies across 19 therapeutic areas and 147 diseases. bioRxiv. 2025. https://doi.org/10.1101/2025.08.28.672795
19.
Lohajová Behulová R, Bugalová A, Bugala J, Struhárňanská E, Šafranek M, Juráš I, et al. Circulating exosomal miRNAs as a promising diagnostic biomarker in cancer. Physiol Res. 2023; 72(S3): S193-S207. https://doi.org/10.33549/physiolres.935153
20.
Zakari S, Niels NK, Olagunju GV, Nnaji PC, Ogunniyi O, Tebamifor M, et al. Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review. Front Oncol. 2024; 14. https://doi.org/10.3389/fonc.2024.1405267
21.
Mokhtari RB, Sambi M, Shekari F, Satari K, Ghafoury R, Ashayeri N, et al. A comprehensive oncological biomarker framework guiding precision medicine. Biomolecules. 2025; 15(9): 1304. https://doi.org/10.3390/biom15091304
22.
Ahmad AKM, Imran M, Ahsan H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics. 2023; 15(6): 1630. https://doi.org/10.3390/pharmaceutics15061630
23.
Dakal TC, Dhakar R, Beura A, Moar K, Maurya PK, Sharma NK, et al. Emerging methods and techniques for cancer biomarker discovery. Pathol Res Pract. 2024; 262: 155567. https://doi.org/10.1016/j.prp.2024.155567
24.
Bommi JR, Kummari S, Lakavath K, Sukumaran RA, Panicker LR, Marty JL, et al. Recent trends in biosensing and diagnostic methods for novel cancer biomarkers. Biosensors. 2023; 13(3): 398. https://doi.org/10.3390/bios13030398
25.
Molla G, Bitew M. The future of cancer diagnosis and treatment: unlocking the power of biomarkers and personalized molecular-targeted therapies. J Mol Pathol. 2025; 6(3): 20. https://doi.org/10.3390/jmp6030020
26.
Wang Z, Zou X, Wang H, Hao Z, Li G, Wang S. Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma. Front Immunol. 2024; 15: 1454720. https://doi.org/10.3389/fimmu.2024.1454720
27.
Najafi NN, Hajihassani H, Azimzadeh Irani M. The impact of artificial intelligence on cancer diagnosis and treatment: a review. Cancer Inform. 2025; 24: 11769351251371273. https://doi.org/10.1177/11769351251371273
28.
Atout M, Elwaheidi H, Maarouf R, Albabtain AA, Alhayli S, Alshaibani A, et al. Minimal residual disease testing for diffuse large b cell lymphoma. Clin Lymphoma Myeloma Leuk. 2025; 25(10): e750-e755. https://doi.org/10.1016/j.clml.2025.05.003
29.
Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. 2019; 14(3): 343-357. https://doi.org/10.1016/j.jtho.2018.11.023
30.
Chakraborty S, Sharma G, Karmakar S, Banerjee S. Multi-OMICS approaches in cancer biology: new era in cancer therapy. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2024; 1870(5): 167120. https://doi.org/10.1016/j.bbadis.2024.167120
31.
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020; 86: 102019. https://doi.org/10.1016/j.ctrv.2020.102019
32.
Prabhash K, Advani SH, Batra U, Biswas B, Chougule A, Ghosh M, et al. Biomarkers in non-small cell lung cancers: Indian Consensus Guidelines for Molecular Testing. Advances in Therapy. 2019; 36(4): 766-85. https://doi.org/10.1007/s12325-019-00903-y
33.
Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Review of Molecular Diagnostics. 2009; 9(5): 455-466. https://doi.org/10.1586/erm.09.25
34.
Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, et al. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw. 2011; 9(Suppl_6): S-1-S-16. https://doi.org/10.6004/jnccn.2011.0138
35.
Netto GJ, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med. 2012; 136(4): 372-390. https://doi.org/10.5858/arpa.2011-0471-RA
36.
Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011; 9(Suppl. 5): S1-32. https://doi.org/10.6004/jnccn.2011.0137
37.
Kulasingam V, Diamandis EP. Tissue culture-based breast cancer biomarker discovery platform. International Journal of Cancer. 2008; 123(9): 2007-2012. https://doi.org/10.1002/ijc.23844
38.
Purkayastha K, Dhar R, Pethusamy K, Srivastava T, Shankar A, Rath GK, et al. The issues and challenges with cancer biomarkers. Journal of Cancer Research and Therapeutics. 2023; 19(Suppl. 1): S20-S35. https://doi.org/10.4103/jcrt.jcrt_384_22
39.
Lewis JM, Heineck DP, Heller MJ. Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids. Expert Rev Mol Diagn. 2015; 15(9): 1187-200. https://doi.org/10.1586/14737159.2015.1069709
40.
Kuhlmann E, Lotta G, Dussault G, Falkenbach M, Correia T. The workforce crisis in healthcare: moving the debate to bridge evidence and policy. The International Journal of Health Planning and Management. 2024; 39(3): 607-613. https://doi.org/10.1002/hpm.3792
41.
Shahazi R, Saddam AI, Islam MR, Rahman MM, Paimard G, Kumer A, et al. Recent progress in Nanomaterial based biosensors for the detection of cancer biomarkers in human fluids. Nano Carbons. 2024; 2(2): 1254. https://doi.org/10.59400/n-c.v2i2.1254
42.
Lawal AO, Ogunniyi TJ, Oludele OI, Olorunfemi OA, Okesanya OJ, Ogaya JB, et al. Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries. Discover Oncology. 2025; 16(1): 137. https://doi.org/10.1007/s12672-025-01877-w
43.
Restrepo JC, Dueñas D, Corredor Z, Liscano Y. Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment. cancers. 2023; 15(13): 3474. https://doi.org/10.3390/cancers15133474
44.
Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines. 2024; 12(12): 2750. https://doi.org/10.3390/biomedicines12122750
45.
Alsaedi S, Ogasawara M, Alarawi M, Gao X, Gojobori T. AI-powered precision medicine: utilizing genetic risk factor optimization to revolutionize healthcare. NAR Genomics and Bioinformatics. 2025; 7(2). https://doi.org/10.1093/nargab/lqaf038
46.
Nwankwo EI, Emeihe EV, Ajegbile MD, Olaboye JA, Maha CC. AI in personalized medicine: enhancing drug efficacy and reducing adverse effects. International Journal of Biology and Pharmacy Research Updates. 2024; 4(8): 806-833. https://doi.org/10.51594/imsrj.v4i8.1453
47.
Obijuru A, Arowoogun JO, Onwumere C, Odilibe IP, Anyanwu EC, Daraojimba AI. Big data analytics in healthcare: a review of recent advances and potential for personalized medicine. International Medical Science Research Journal. 2024; 4(2). https://doi.org/10.51594/imsrj.v4i2.810
Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
